Skip to main content
. 2013 Mar 25;168(8):1878–1888. doi: 10.1111/bph.12079

Figure 5.

Figure 5

In vivo treatment with HET0016 attenuates vascular NF-κB activation in SHR. (A) shows NF-κB binding activity in nuclear extracts from carotid arteries isolated from control WKY rats, SHRs and SHRs treated with HET0016 (SHR + HET0016; 10 mg·kg−1·per day, i.p., n = 6 for each data point). (B) effect of 20-HETE (10−7 mol·L−1) on NF-κB activation measured by dual-luciferase reporter assay in cultured rat cerebromicrovascular endothelial cells (CMVEC) in the absence and presence of TP receptor blocker SQ 29548 (10−6 mol·L−1). Data are mean ± SEM *P < 0.05 versus control; #P < 0.05 versus untreated.